Therapy Areas: Oncology
CHMP backs Gilead's Trodelvy-Keytruda combination for first-line metastatic triple-negative breast cancer
24 July 2026 - Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) announced on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recom...
Active Biotech doses first patient in amended tasquinimod myelofibrosis study
24 July 2026 - Swedish biotechnology company Active Biotech AB (STO:ACTI) announced on Friday that the first patient has been dosed in the amended Phase Ib/II clinical study of tasquinimod in patients...
Bio-Thera Solutions reports first patient dosed in Phase 1 study of BAT8013
24 July 2026 - Commercial-stage pharmaceutical company Bio-Thera Solutions Ltd (SH:688177) announced on Thursday that dosing has begun in a Phase 1 clinical study evaluating BAT8013, an antibody drug ...
EU approves AstraZeneca's Etcamah combination for 1st-line ER-positive advanced breast cancer
23 July 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) announced on Thursday it has secured European Union approval for Etcamah (camizestrant) combined with a CDK4/6 ...
BeOne Medicines expands US manufacturing with USD300m investment
23 July 2026 - Oncology company BeOne Medicines Ltd (NASDAQ:ONC) (HKEX:06160) (SSE:688235) announced on Thursday that it will invest USD300m to expand its flagship manufacturing and research and devel...
GSK's Jideytro (zidesamtinib) gains US approval for previously treated ROS1-positive NSCLC
23 July 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) announced on Wednesday that the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhib...